A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome

PHASE4TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Suspected Heparin-Induced Thrombocytopenia
Interventions
DRUG

Desirudin or Argatroban®

Desirudin 15mg SC Argatroban® IV dosing per Package Insert

Trial Locations (24)

10011

St Vincent's Hosptial -Manhattan, Manhattan

10029

Mount Sinai Clinical & Translational Research Institute, New York

10467

Montefiore Medical Center, Moses Division, The Bronx

11030

North Shore University Hospital, Manhasset

14642

University of Rochester Medical Center, Rochester

20010

Washington Regional Cardiac Surgery, Washington D.C.

25304

Charleston Area Medical Center, Charleston

30308

Emory University, Emory Crawford Long Hospital, Atlanta

32801

Florida Hospital Cardiovascular Research, Orlando

33606

University of South Florida, Tampa General Hospital, Tampa

42314

Cardiothoracic Vascular Surgial Specialists, Columbus

43210

The Ohio State University Medical Center, Columbus

44195

The Cleveland Clinic, Cleveland

48073

William Beaumont Hospital, Royal Oak

51101

Mercy Medical Center, Sioux City

55902

St Mary's Hospital Rochester, Mayo Clinic, Rochester

Forsyth Regional Medical Center, Winston-Salem

60435

Provena St. Joseph's Medical Center, Joliet

77030

Methodist Hospital, Houston

80045

University of Colorado Health Science Center, Aurora

84132

University of Utah Hospital, Salt Lake City

96819

Kaiser Permanente Medical Center, Honolulu

04102

Maine Medical Center, Portland

08903

UMDNJ-Robert Wood Johnson Medical School, New Brunswick

Sponsors
All Listed Sponsors
lead

Canyon Pharmaceuticals, Inc.

INDUSTRY